Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

Status: Recruiting

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

• Willing to participate in the study and provide written informed consent.

• Male and female adults aged > 18 years.

• Must have NASH and fibrosis on a liver biopsy sample

• If a historical liver biopsy is used for Screening, obtained within 6 months prior to Screening;

• Subjects may have a diagnosis of T2DM

Exclusion Criteria:

• History or presence of liver disease (other than NAFLD or NASH)

• History or presence of cirrhosis and/or history or presence of hepatic decompensation

Conditions & Interventions

Interventions:
Drug: AXA1125, Drug: Placebo
Conditions:
Non Alcoholic Steatohepatitis (NASH)
Keywords:
Steatosis, Lobular inflammation, Ballooning, Liver biopsy, Liver fat, Liver stiffness, NASH, Aminio Acids, Fibrosis

More Information

Contact(s): Margaret Koziel, MD - clinicaltrials@axcellahealth.com
Principal Investigator: Siddiqui, Mohammad, S
Phase: Phase 2
IRB
Number: HM20022234
System ID: NCT04880187
